GLP-1 (7-36) amide

Summary

Glucagon‑like peptide‑1 (7‑36) amide is the native, amidated form of the incretin hormone released from intestinal L‑cells after a meal. It stimulates glucose‑dependent insulin secretion, suppresses glucagon release, slows gastric emptying and reduces food intake. Because it is rapidly degraded by dipeptidyl‑peptidase‑4, its circulating half‑life is very short, limiting its direct therapeutic use. Research continues to explore its central nervous system actions, cardiovascular effects and the activity of its breakdown products.

Mechanism of Action

The peptide binds the G‑protein‑coupled GLP‑1 receptor (GLP‑1R) expressed on pancreatic β‑cells, hypothalamic neurons and peripheral tissues. Receptor activation raises intracellular cAMP, enhancing insulin exocytosis in a glucose‑dependent manner and inhibiting glucagon release. In the brain, GLP‑1R activation modulates neurotransmitter release, appetite‑regulating circuits and autonomic outputs that slow gastric motility and lower blood pressure. Metabolites generated by DPP‑4 (e.g., GLP‑1 9‑36) can act through GLP‑1R‑independent pathways that influence hepatic glucose production and cardiomyocyte survival.

What the Research Shows

Early work identified GLP‑1 (7‑36) amide as an intestinal hormone, but later studies showed expression of its precursor in the brain and the presence of GLP‑1 receptors in hypothalamic nuclei, supporting a neuropeptide role. Central (intracerebroventricular) administration in rodents reduced food and water intake and altered arterial pressure, indicating centrally mediated satiety and cardiovascular effects. The peptide is rapidly cleaved by DPP‑4 to GLP‑1 (9‑36) amide, the predominant circulating form; additional cleavage by neprilysin yields shorter fragments that display insulin‑mimetic, antioxidant and anti‑apoptotic actions independent of GLP‑1R. Reviews highlight extrapancreatic actions such as inhibition of gastric emptying, modulation of hepatic glucose output, and direct cardioprotective effects, while noting that most cardiovascular and neuroprotective data derive from animal models or in‑vitro experiments. The short half‑life prompted development of DPP‑4 inhibitors and DPP‑4‑resistant GLP‑1 analogues, underscoring the research focus on prolonging native peptide activity.

Reported Benefits

Preclinical data support several physiological benefits of GLP‑1 (7‑36) amide: it enhances glucose‑dependent insulin secretion, lowers post‑prandial glucose, suppresses appetite and reduces caloric intake, and slows gastric emptying, contributing to improved glycaemic control and weight management. Animal studies also report reductions in arterial blood pressure, heart rate modulation, and preservation of cardiomyocyte viability, suggesting potential cardioprotective actions. Metabolites such as GLP‑1 (9‑36) may independently inhibit hepatic glucose production and exert antioxidant effects, expanding the therapeutic interest beyond the parent peptide.

Limitations of the Evidence

The native peptide’s clinical utility is limited by an extremely short plasma half‑life due to rapid DPP‑4 cleavage, necessitating continuous infusion or modification for therapeutic use. Most evidence for central nervous system, cardiovascular and metabolite actions comes from rodent experiments, intracerebroventricular dosing, or review‑based synthesis rather than large‑scale human trials. Consequently, definitive efficacy and safety data in patients are lacking, and the peptide remains a research‑only compound. The relevance of GLP‑1‑independent metabolite effects to human disease remains uncertain.

Safety Considerations

Animal investigations indicate that central GLP‑1 (7‑36) amide can lower blood pressure and alter heart rate, suggesting possible hypotensive or tachycardic effects at high concentrations. The peptide is rapidly degraded, reducing systemic exposure, and no human safety data are available for the native form. Because it is not an approved drug, adverse‑event profiles are limited to preclinical observations, and caution is advised when extrapolating to clinical contexts. Potential risks may include nausea, vomiting or gastrointestinal slowing, as seen with GLP‑1‑based therapies, but these have not been directly documented for the unmodified peptide.

How It Is Administered

Research protocols have employed intravenous infusion and subcutaneous injection of GLP‑1 (7‑36) amide in animal models. Some studies also used intracerebroventricular delivery to assess central effects. No commercial formulation exists for human use, and dosing regimens are confined to experimental settings.

Routes of Administration

Goals & Uses

• NeuroprotectionNeurologyLow
• Glycemic control (type 2 diabetes)Metabolic / EndocrineHigh
• Cardiovascular risk reductionCardiovascularModerate
• CardioprotectionCardiovascularModerate
• Weight reductionMetabolicModerate
• Glycemic control in type 2 diabetesMetabolicHigh
• Body weight reduction / appetite suppressionMetabolic / ObesityModerate
• Beta-cell preservationMetabolicModerate

Contraindications

• Personal or family history of medullary thyroid carcinomaOncologicHigh
• Severe hypersensitivity to GLP-1 peptidesImmunologicalHigh
• Multiple endocrine neoplasia syndrome type 2 (MEN2)OncologicHigh
• Multiple endocrine neoplasia type 2OncologyHigh
• Medullary thyroid carcinomaOncologyHigh

Adverse Effects

• PancreatitisGastrointestinalRareInflammation of the pancreas
• HypoglycemiaMetabolicUncommonAbnormally low blood glucose
• Injection site reactionsLocalUncommon
• TachycardiaCardiovascularUncommonAbnormally fast heart rate
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• VomitingGastrointestinalCommonForceful expulsion of stomach contents

Drug Interactions

• InsulinModerateMay increase risk of low blood sugar
• Insulin and insulin secretagoguesModerate
• Oral medications with narrow therapeutic indexLow
• SulfonylureasModerateMay increase risk of low blood sugar
• DPP-4 inhibitors (e.g., sitagliptin)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• Personal or family history of pancreatitisGastrointestinalRelative
• Severe renal impairmentOrgan ImpairmentRelative
• Pediatric populationAgeRelative
• PediatricsAgeRelative

Regulatory Status

• European UnionInvestigationalSame as US.
• United StatesInvestigationalNot an approved drug; used as research peptide.
• United KingdomUnapprovedNot approved by MHRA. Research use only; GLP-1 analogs are approved through EMA/MHRA pathways.

The native peptide is not approved as a drug product in any major jurisdiction. It serves as the pharmacological reference compound and is used in academic and clinical research settings. Approved GLP-1 receptor agonist drugs are structurally modified analogs designed to resist DPP-4 degradation.

Evidence & Sources

• Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide
  Journal ArticleModerateBlázquez E, et al.1998-01-01T00:00:00.000000Z
• GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products
  Journal ArticleModerateGuglielmi V, Sbraccia P2017-01-01T00:00:00.000000Z
• Circulation and degradation of GIP and GLP-1
  Journal ArticleModerateDeacon CF2004-01-01T00:00:00.000000Z
• From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
  Journal ArticleModerateHolst JJ2019-01-01T00:00:00.000000Z
• Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
  Journal ArticleModerateLi J, et al.2017-01-01T00:00:00.000000Z
• Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides
  Journal ArticleModerateAbu-Hamdah R, et al.2009-01-01T00:00:00.000000Z

Frequently Asked Questions